@article{6eb7148bea3d475e954313af2c72c690,
title = "Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel",
abstract = "Haemophagocytic lymphohistiocytosis-like toxicity following chimeric antigen receptor T cells (CAR-HLH) is being increasingly recognized, while published data are limited and criteria for recognition are elusive. We describe three patients who developed CAR-HLH after infusion of brexucabtagene autoleucel (n = 2) or axicabtagene ciloleucel (n = 1). All three patients presented following cytokine release syndrome, with fever, recurrent or worsening cytopenias, hyperferritinaemia, elevated soluble interleukin (IL)-2 receptor, hypofibrinogenaemia, hypertriglyceridaemia, elevated liver transaminases, and decreasing C-reactive protein and IL-6. Clinical improvement following treatment with anakinra (n = 2) and ruxolitinib (n = 1) was observed. Our report offers an opportunity for prompt recognition and initiation of potentially life-saving treatment for CAR-HLH.",
keywords = "CAR T cells, HLH-like syndrome, delayed hyperinflammatory syndrome",
author = "Porter, {Timothy J.} and Ana Lazarevic and Ziggas, {Jamie E.} and Ephraim Fuchs and Kiryoung Kim and Helen Byrnes and Leo Luznik and Javier Bola{\~n}os-Meade and Ali, {Syed Abbas} and Shah, {Nirali N.} and Nina Wagner-Johnston and Tania Jain",
note = "Funding Information: Timothy J. Porter reports consultancy with Medexus Pharmaceuticals. Jamie E. Ziggas reports consultancy with Seagen. Nina Wagner‐Johnston has served on advisory boards for Epizyme and Seattle Genetics and receives research funding from ADC Therapeutics, Regeneron and Genentech. Tania Jain reports institutional research support from CTI Biopharma, Incyte and Syneos Health; advisory board participation with Care Dx, Incyte, Abbvie, Kite and Bristol Myers Squibb. All other authors report no conflicts of interest. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, or imply endorsement by the U.S. Government. Publisher Copyright: {\textcopyright} 2022 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2022",
month = dec,
doi = "10.1111/bjh.18454",
language = "English (US)",
volume = "199",
pages = "720--727",
journal = "British journal of haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",
}